Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
deals
life sciences
national blog main
national top stories
new york blog main
new york top stories
novartis
3
×
abbvie
alzheimer's disease
amgen
biotech
boulder/denver blog main
boulder/denver top stories
cystic fibrosis
detroit blog main
detroit top stories
diagnostics
gene therapy
gilead sciences
indiana blog main
indiana top stories
merck
national
pfizer
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
spark therapeutics
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
What
biggest
3
×
acquisitions
bio
ceo
drug
roundup
age
albert
bigger
bourla
build
buy
come
company
company’s
crispr
daniel
deal
debut
dyne’s
emerging
future
gave
gene
gilead
imports
j
johnson
maker
maps
measured
meiragtx
microbiome
morning
moves
openly
o’day
past
patients
pfizer
Language
unknown
unset
Current search:
novartis
×
biggest
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
